| 李 倩,宫鹏飞,张 明,白 燕,安 毅.注射用地尔硫卓联合前列地尔注射液对射血分数保留型心衰患者心功能、血清炎症因子和氧化应激的影响[J].,2020,(20):3997-4000 |
| 注射用地尔硫卓联合前列地尔注射液对射血分数保留型心衰患者心功能、血清炎症因子和氧化应激的影响 |
| Effects of Diltiazem for Injection Combined with Alprostadil Injection on Cardiac Function, Serum Inflammatory Factors and Oxidative Stress in Patients with Ejection Fraction Preserved Heart Failure |
| 投稿时间：2020-05-27 修订日期：2020-06-18 |
| DOI：10.13241/j.cnki.pmb.2020.20.043 |
| 中文关键词: 注射用地尔硫卓 前列地尔注射液 射血分数保留型心衰 心功能 炎症因子 氧化应激 |
| 英文关键词: Diltiazem for injection Alprostadil injection Ejection fraction preserved heart failure Cardiac function Inflammatory factors Oxidative stress |
| 基金项目:山东省卫计委科技发展计划项目（2014WS0173） |
|
| 摘要点击次数: 837 |
| 全文下载次数: 402 |
| 中文摘要: |
| 摘要 目的：注射用地尔硫卓联合前列地尔注射液对射血分数保留型心衰（HFpEF）患者心功能、血清炎症因子和氧化应激的影响。方法：选取2016年3月至2020年3月期间于齐都医院接受治疗的HFpEF患者108例，根据奇偶排序法分为对照组54例、研究组54例，对照组患者给予注射用地尔硫卓治疗，研究组患者给予注射用地尔硫卓联合前列地尔注射液治疗，疗程为2周。对比两组治疗2周后的疗效，记录两组治疗期间不良反应发生情况。对比两组治疗前、治疗2周后的二尖瓣舒张早期血流峰速度/心房收缩期二尖瓣口最大血流流速（E/A）以及二尖瓣舒张早期血流峰速度/二尖瓣环舒张早期运动峰速度（E/E'）、B型尿钠肽（BNP）、C反应蛋白（CRP）、白细胞介素（IL）-6、巨噬细胞移动抑制因子（MIF）、鸟嘌呤（8-OHdG）、超氧化物歧化酶（SOD）、丙二醛（MDA）。结果：与对照组的总有效率75.93%（41/54）相比，研究组的总有效率92.59%（50/54）更高（P<0.05）。研究组治疗2周后BNP、E/E'低于对照组，E/A高于对照组（P<0.05）。研究组治疗2周后IL-6、CRP、MIF低于对照组（P<0.05）。研究组治疗2周后8-OhdG、MDA低于对照组，SOD高于对照组（P<0.05）。两组均未见明显不良反应发生。结论：注射用地尔硫卓联合前列地尔注射液能显著改善HFpEF患者心功能，改善机体血清炎症因子和氧化应激，安全有效。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of diltiazem for injection combined with alprostadil injection on cardiac function, serum inflammatory factors and oxidative stress in patients with ejection fraction preserved heart failure (HFPEF). Methods: 108 HFPEF patients who were admitted and treated in Qidu hospital from March 2016 to March 2020 were selected, they were divided into control group of 54 cases, study group of 54 cases according to parity sorting method, patients in control group were treated with diltiazem for injection, patients in study group were treated with diltiazem for injection combined with alprostadil injection, the course of treatment was 2 weeks. The curative effects of two groups after 2 weeks of treatment were compared, the incidence of adverse reactions in the two groups was recorded. the peak velocity of mitral early diastolic flow/maximum flow velocity of atrial systolic mitral valve orifice (E/A) and peak velocity of mitral early diastolic flow/early diastolic blood flow velocity (E/E'), B-type natriuretic peptide (BNP), C-reactive protein (CRP), interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), guanine (8-OHdG), superoxide dismutase (SOD), malondialdehyde (MDA) were compared between the two groups before treatment, after 2 weeks of treatment. Results: Compared with 75.93% (41/54) of the total effective rate in control group, 92.59% (50/54) of the total effective rate in study group was higher (P<0.05). BNP and E / E 'of study group were lower than those of control group, E/A was higher than control group after 2 weeks of treatment (P<0.05). IL-6, CRP, MIF in study group were lower than those of control group after 2 weeks of treatment (P<0.05). 8-OHdG, MDA in study group were lower than those in control group, SOD was higher than control group after 2 weeks of treatment (P<0.05). There was no obvious adverse reactions occurred in both groups. Conclusion: Diltiazem for injection combined with alprostadil injection can significantly improve cardiac function in patients with HFPEF, improve the body serum inflammatory factors and oxidative stress, which is safe and effective. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
